Services
Our services are centred around intellectual property that can be registered. We protect innovation, design, and branding across all sectors of industry, and at all stages in the supply chain.
For each IP right we offer services covering strategic advice, pre-registration searches, registrations and renewals, oppositions and dispute resolution. We handle work throughout the world, working with local colleagues in over 100 countries.
Services
Sectors
Our attorneys specialise in one or more sectors of industry, which enables them to provide quality advice with a commercial focus.
Our patent specialists have detailed understanding of the background technology, which ensures that your patent applications are prepared with the correct scope, reducing the likelihood of challenges from third parties and objections from the patent office.
They also advise whether other forms of protection would be more appropriate. Our brand specialists work with brand managers for leading brands and their advice is commercially focussed making sure that you get the best value from your budget.
Sectors
Robin Ellis in our Munich office discusses some of the highlights of the newly introduced SPC manufacturing waiver.
The referral to the Enlarged Board of Appeal relating to plants obtained by means of an essentially biological process.
We explore the reasoning behind the use of animal models, the acknowledged limitations of animal data for predicting treatment effects in humans and the approach taken by the EPO in assessing whether such data can be used to demonstrate a medical use invention.
Second medical use claims are designed to protect substances or compositions for use in new medical treatments. Numerous decisions of the Technical Boards of Appeal of the EPO have confirmed that second medical use claims cannot be used to protect medical devices. However, as is so often the case in patent law, scientific advancements are beginning to blur the technical difference on which the legal distinction between medical devices and substances is based.
In previous articles we considered the increasing significance of plausibility at the EPO, particularly when assessing inventive step and sufficiency.
This English high court decision relates to the question of infringement of a US patent. At first sight this may seem a little odd – why is an English court deciding on a matter of US patent infringement?
Is there a high chance of US and UK courts grappling with medicinal cannabis patents?The US and UK patent offices have granted a number of patents relating to the therapeutic use of cannabis derived products.
The CJEU ruled that organisms obtained by mutagenesis are genetically modified organisms (GMOs) and are subject to the obligations laid down by the GMO Directive